Neurology Devices Market by Product (CSF Management Devices, Interventional Neurology, Neurostimulation), Application (Chronic Pain, Epilepsy & Seizure Disorders, Mental Health Disorders), End User, Distribution Channel - Global Forecast 2025-2032
Description
The Neurology Devices Market was valued at USD 12.74 billion in 2024 and is projected to grow to USD 13.96 billion in 2025, with a CAGR of 10.44%, reaching USD 28.21 billion by 2032.
Unveiling the Future of Neurology Devices Through Comprehensive Analysis of Drivers, Innovations, and Market Dynamics Guiding Strategic Decision Making
The neurology devices sector stands at a pivotal moment, driven by the convergence of demographic trends, technological breakthroughs, and shifting clinical demands. As populations age and the prevalence of neurological disorders rises, healthcare providers face unprecedented pressure to adopt advanced diagnostic and therapeutic tools. Concurrently, regulatory agencies are streamlining approval pathways, fostering faster market entry for safety-proven innovations. This environment demands a holistic understanding of underlying forces and an agile response to emerging opportunities.
In this dynamic landscape, innovations in minimally invasive procedures, digital platforms, and neurostimulation technologies are redefining patient care. Collaborative research initiatives are amplifying translational efforts, while cross-border partnerships broaden access to cutting-edge treatments. At the same time, cost-containment pressures and evolving reimbursement models require a delicate balance between clinical outcomes and economic sustainability.
This executive summary provides a structured exploration of the transformative shifts shaping the neurology devices market. By examining tariff implications, key segmentation insights, regional dynamics, and leading competitive strategies, readers will gain a comprehensive framework to inform strategic decision making. The actionable recommendations and methodological rigor presented here equip stakeholders with the clarity needed to navigate complexity and drive meaningful impact.
Examining Pivotal Technological, Regulatory, and Clinical Milestones Reshaping the Global Neurology Device Environment and Strategic Trends
Technological breakthroughs are rewriting the rules of neurology device development and deployment. Advancements in artificial intelligence–enabled imaging, robotics-assisted interventions, and precision neurostimulation have accelerated diagnostic accuracy and therapeutic efficacy. Moreover, the emergence of digital therapeutics and wearable sensors fosters real-time monitoring and personalized treatment adjustments, extending the continuum of care beyond traditional settings.
Regulatory frameworks are evolving in parallel, with accelerated approval pathways and conditional clearances encouraging earlier patient access to novel devices. Heightened post-market surveillance and data transparency requirements, however, call for robust evidence generation and lifecycle management strategies. These regulatory dynamics are driving companies to integrate proactive compliance and adaptive trial designs into core development plans.
Clinically, there is a marked shift toward patient-centric and home-based care models, supported by minimally invasive technologies that reduce recovery times and hospital stays. Telehealth integration and remote monitoring tools are gaining prominence, empowering patients and providers to collaborate more effectively. The convergence of these technological, regulatory, and clinical milestones is reshaping the global neurology device environment and setting new benchmarks for performance and accessibility
Assessing the Collective Impact of Newly Instituted United States Tariffs on Neurology Device Supply Chains, Competitive Dynamics, and Cost Structures
The introduction of comprehensive United States tariffs in 2025 has prompted a recalibration of neurology device supply chain and cost structures. Manufacturers that historically relied on international sourcing are now evaluating nearshoring options to mitigate import duties and avoid potential delays at customs. This strategic realignment not only affects procurement costs but also impacts lead times and supplier relationships across multiple tiers of the value chain.
Distributors and end users are experiencing ripple effects in pricing negotiations and inventory management. As landed costs rise, some healthcare providers are exploring localized manufacturing partnerships and consortium purchasing agreements to preserve budgetary flexibility. At the same time, emerging competitors from regions with favorable trade agreements are gaining traction, intensifying competitive pressures on established players.
In response, industry leaders are reassessing their commercialization strategies by optimizing product portfolios, consolidating high-volume SKUs, and leveraging digital platforms to streamline ordering and fulfillment. Collaborative efforts between public institutions and private enterprises are also taking shape to secure critical components and ensure continuity of supply. These collective adjustments underscore the need for agile operational frameworks that can adapt swiftly to evolving trade landscapes
Discovering Deep Insights into Neurology Device Market Segmentation Based on Product, Application, End User, and Channel Preferences for Targeted Strategy Development
Understanding the neurology devices landscape requires a nuanced view of product, application, end user, and distribution channel dynamics. Within product categories, devices for cerebrospinal fluid management encompass both cerebral external drainage and cerebral shunts, addressing critical hydrocephalus conditions, while interventional neurology technologies span aneurysm coiling and embolization-including embolic coils, flow diversion devices, liquid embolic reagents-alongside cerebral balloon angioplasty and stents such as balloon occlusion devices, carotid artery stents, and filter devices, as well as neurothrombectomy tools like clot retrievers, snare devices, and suction aspiration devices. Neurostimulation solutions extend across deep brain stimulation, gastric electric stimulation, sacral nerve stimulation, spinal cord stimulation, and vagus nerve stimulation, and neurosurgery navigation and resection rely on aneurysm clips, neuroendoscopes, stereotactic systems, and ultrasonic aspirators.
Applications stretch from chronic pain treatments to epilepsy and seizure disorders, which are further differentiated between diagnostic and monitoring systems and seizure control devices, as well as mental health disorders including anxiety, depression, and schizophrenia. In neurodegenerative disorders such as Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and Parkinson’s disease, the demand for precision therapies continues to grow. Neurovascular disorders, spinal cord injuries, stroke interventions-comprising hemorrhagic and ischemic stroke devices and stroke rehabilitation products-and traumatic brain injury treatments complete the clinical spectrum.
Key stakeholder environments range from academic and research institutes to diagnostic centers, home care settings, hospitals, neurology clinics, and rehabilitation centers, each driving unique procurement and usage patterns. Distribution channels, whether offline or online, further shape market access and customer engagement strategies for targeted strategy development
Unraveling Regional Variations and Growth Catalysts Influencing the Americas, Europe, Middle East & Africa, and Asia-Pacific Neurology Device Markets
Regional dynamics in the neurology devices arena reflect distinct growth catalysts and market characteristics. In the Americas, robust research and development ecosystems, comprehensive reimbursement frameworks, and early adoption cultures have established a fertile ground for high-value device penetration. The presence of leading academic institutions and clinical trial networks accelerates innovation cycles and informs evidence-based rollout strategies.
In the Europe, Middle East & Africa region, heterogeneous regulatory regimes and diverse healthcare infrastructure create both challenges and opportunities. Western Europe’s stringent approval standards drive product differentiation and clinical validation, while emerging markets in the Middle East and Africa are witnessing increased investment in neurological care capabilities. Collaborative initiatives among regional health authorities are facilitating access to advanced therapies, even as cost containment remains a primary focus.
The Asia-Pacific market is characterized by rapid expansion of healthcare infrastructure, government-led neurohealth programs, and growing middle-class demand for advanced treatments. Local manufacturing incentives and public-private partnerships are enhancing device affordability, while rising incidence of neurological disorders and greater awareness of outcomes are fueling adoption. Understanding these regional nuances is crucial for stakeholders seeking to align product strategies with localized priorities and growth trajectories
Profiling Leading Stakeholders and Competitive Strategies Driving Innovation, Partnerships, and Market Positioning in the Neurology Devices Sector
The competitive landscape of neurology devices is defined by a combination of global leaders and emerging innovators. Established medical technology companies are leveraging extensive distribution networks, deep clinical trial experience, and broad regulatory expertise to maintain market position. These organizations routinely invest in R&D to enhance product portfolios, strengthen intellectual property assets, and integrate digital capabilities such as remote monitoring and data analytics.
At the same time, mid-size enterprises and specialized firms are driving innovation in niche areas like targeted neurostimulation, bioresorbable materials, and AI-driven diagnostics. Strategic collaborations with academic centers and technology startups enable rapid iteration of proof-of-concept devices and support accelerated commercialization pathways. Mergers, acquisitions, and joint ventures continue to be prominent tactics for expanding geographic reach, securing new clinical indications, and consolidating complementary product lines.
In response to evolving patient needs and regulatory expectations, leading stakeholders are emphasizing post-market studies and real-world evidence generation. Partnerships with payers and health systems are increasingly structured to demonstrate health economics and outcomes benefits, thereby facilitating market access and reimbursement. This multifaceted competitive dynamic underscores the importance of adaptive strategies centered on innovation, collaboration, and evidence-based value propositions
Identifying Actionable Strategies for Industry Leaders to Navigate Regulatory Shifts, Technological Advances, and Evolving Clinical Needs in Neurology Devices
Industry leaders must adopt a multifaceted approach to navigate the complex neurology devices ecosystem. Companies should prioritize investments in digital health platforms that enhance remote patient monitoring and streamline data collection, enabling more responsive therapy adjustments and stronger clinical evidence. In parallel, diversifying manufacturing footprints and nurturing relationships with regional suppliers will mitigate tariff-related risks and improve supply chain resilience.
Embracing patient-centric design through co-development with clinicians and end users drives both therapeutic efficacy and market acceptance. Collaborative alliances with academic institutions, technology startups, and contract research organizations can expedite innovation cycles and support adaptive trial designs. Furthermore, leveraging real-world evidence to articulate clear health economic value will be instrumental for securing favorable reimbursement and forging partnerships with payers.
To stay ahead of regulatory shifts, organizations should maintain proactive engagement with health authorities and invest in robust post-market surveillance systems. This vigilance not only ensures compliance but also uncovers safety signals that refine product lifecycle strategies. By aligning these initiatives with targeted segmentation insights and regional priorities, companies can capitalize on emerging opportunities and solidify their leadership in the neurology devices arena
Detailing Rigorous Research Methodology Encompassing Primary Interviews, Secondary Data Review, and Qualitative-Quantitative Analyses to Ensure Data Integrity and Reliability
This study is grounded in a rigorous methodology that merges qualitative and quantitative research techniques to ensure comprehensive coverage and data integrity. Primary research efforts included in-depth interviews with key opinion leaders, clinicians, supply chain executives, and regulatory specialists, whose insights illuminated emerging trends, adoption barriers, and market dynamics across global regions.
Secondary research encompassed an extensive review of peer-reviewed journals, regulatory filings, industry publications, and published conference proceedings. This data was meticulously triangulated with proprietary databases and public financial disclosures to construct a robust framework for analysis. Quantitative modeling techniques were applied to synthesize categorical data, while sensitivity analyses tested the resilience of key findings against potential market shifts.
To maintain methodological transparency, all data sources were documented and cross-verified through internal peer review. Validation workshops with domain experts ensured that assumptions and interpretations aligned with real-world experiences. This structured approach yields a reliable foundation for stakeholders to make informed strategic decisions and confidently navigate the evolving neurology devices environment
Concluding Key Takeaways Emphasizing Strategic Implications, Market Evolution, and the Path Forward for Neurology Device Stakeholders
The neurology devices sector is undergoing transformative shifts driven by technological innovation, regulatory evolution, and changing patient care paradigms. Navigating the complexities introduced by new tariff regimes requires agile supply chain strategies and strategic partnerships. Meanwhile, in-depth segmentation insights illuminate high-potential areas such as neurostimulation, targeted stroke interventions, and home-based monitoring solutions.
Regional nuances-from the advanced reimbursement frameworks in the Americas to the infrastructure growth in Asia-Pacific and the diverse regulatory landscapes in Europe, Middle East & Africa-underscore the need for domestically tailored approaches. Competitive positioning hinges on a dual focus: continuous R&D investments that deliver clinical differentiation and robust evidence portfolios that satisfy both regulatory bodies and payers.
By integrating actionable recommendations-such as digital health investments, patient-centric co-development, and real-world evidence generation-stakeholders can respond effectively to evolving clinical needs and market dynamics. The convergence of these elements charts a clear path forward, enabling companies to secure leadership positions and drive positive patient outcomes in the neurology devices arena
Note: PDF & Excel + Online Access - 1 Year
Unveiling the Future of Neurology Devices Through Comprehensive Analysis of Drivers, Innovations, and Market Dynamics Guiding Strategic Decision Making
The neurology devices sector stands at a pivotal moment, driven by the convergence of demographic trends, technological breakthroughs, and shifting clinical demands. As populations age and the prevalence of neurological disorders rises, healthcare providers face unprecedented pressure to adopt advanced diagnostic and therapeutic tools. Concurrently, regulatory agencies are streamlining approval pathways, fostering faster market entry for safety-proven innovations. This environment demands a holistic understanding of underlying forces and an agile response to emerging opportunities.
In this dynamic landscape, innovations in minimally invasive procedures, digital platforms, and neurostimulation technologies are redefining patient care. Collaborative research initiatives are amplifying translational efforts, while cross-border partnerships broaden access to cutting-edge treatments. At the same time, cost-containment pressures and evolving reimbursement models require a delicate balance between clinical outcomes and economic sustainability.
This executive summary provides a structured exploration of the transformative shifts shaping the neurology devices market. By examining tariff implications, key segmentation insights, regional dynamics, and leading competitive strategies, readers will gain a comprehensive framework to inform strategic decision making. The actionable recommendations and methodological rigor presented here equip stakeholders with the clarity needed to navigate complexity and drive meaningful impact.
Examining Pivotal Technological, Regulatory, and Clinical Milestones Reshaping the Global Neurology Device Environment and Strategic Trends
Technological breakthroughs are rewriting the rules of neurology device development and deployment. Advancements in artificial intelligence–enabled imaging, robotics-assisted interventions, and precision neurostimulation have accelerated diagnostic accuracy and therapeutic efficacy. Moreover, the emergence of digital therapeutics and wearable sensors fosters real-time monitoring and personalized treatment adjustments, extending the continuum of care beyond traditional settings.
Regulatory frameworks are evolving in parallel, with accelerated approval pathways and conditional clearances encouraging earlier patient access to novel devices. Heightened post-market surveillance and data transparency requirements, however, call for robust evidence generation and lifecycle management strategies. These regulatory dynamics are driving companies to integrate proactive compliance and adaptive trial designs into core development plans.
Clinically, there is a marked shift toward patient-centric and home-based care models, supported by minimally invasive technologies that reduce recovery times and hospital stays. Telehealth integration and remote monitoring tools are gaining prominence, empowering patients and providers to collaborate more effectively. The convergence of these technological, regulatory, and clinical milestones is reshaping the global neurology device environment and setting new benchmarks for performance and accessibility
Assessing the Collective Impact of Newly Instituted United States Tariffs on Neurology Device Supply Chains, Competitive Dynamics, and Cost Structures
The introduction of comprehensive United States tariffs in 2025 has prompted a recalibration of neurology device supply chain and cost structures. Manufacturers that historically relied on international sourcing are now evaluating nearshoring options to mitigate import duties and avoid potential delays at customs. This strategic realignment not only affects procurement costs but also impacts lead times and supplier relationships across multiple tiers of the value chain.
Distributors and end users are experiencing ripple effects in pricing negotiations and inventory management. As landed costs rise, some healthcare providers are exploring localized manufacturing partnerships and consortium purchasing agreements to preserve budgetary flexibility. At the same time, emerging competitors from regions with favorable trade agreements are gaining traction, intensifying competitive pressures on established players.
In response, industry leaders are reassessing their commercialization strategies by optimizing product portfolios, consolidating high-volume SKUs, and leveraging digital platforms to streamline ordering and fulfillment. Collaborative efforts between public institutions and private enterprises are also taking shape to secure critical components and ensure continuity of supply. These collective adjustments underscore the need for agile operational frameworks that can adapt swiftly to evolving trade landscapes
Discovering Deep Insights into Neurology Device Market Segmentation Based on Product, Application, End User, and Channel Preferences for Targeted Strategy Development
Understanding the neurology devices landscape requires a nuanced view of product, application, end user, and distribution channel dynamics. Within product categories, devices for cerebrospinal fluid management encompass both cerebral external drainage and cerebral shunts, addressing critical hydrocephalus conditions, while interventional neurology technologies span aneurysm coiling and embolization-including embolic coils, flow diversion devices, liquid embolic reagents-alongside cerebral balloon angioplasty and stents such as balloon occlusion devices, carotid artery stents, and filter devices, as well as neurothrombectomy tools like clot retrievers, snare devices, and suction aspiration devices. Neurostimulation solutions extend across deep brain stimulation, gastric electric stimulation, sacral nerve stimulation, spinal cord stimulation, and vagus nerve stimulation, and neurosurgery navigation and resection rely on aneurysm clips, neuroendoscopes, stereotactic systems, and ultrasonic aspirators.
Applications stretch from chronic pain treatments to epilepsy and seizure disorders, which are further differentiated between diagnostic and monitoring systems and seizure control devices, as well as mental health disorders including anxiety, depression, and schizophrenia. In neurodegenerative disorders such as Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and Parkinson’s disease, the demand for precision therapies continues to grow. Neurovascular disorders, spinal cord injuries, stroke interventions-comprising hemorrhagic and ischemic stroke devices and stroke rehabilitation products-and traumatic brain injury treatments complete the clinical spectrum.
Key stakeholder environments range from academic and research institutes to diagnostic centers, home care settings, hospitals, neurology clinics, and rehabilitation centers, each driving unique procurement and usage patterns. Distribution channels, whether offline or online, further shape market access and customer engagement strategies for targeted strategy development
Unraveling Regional Variations and Growth Catalysts Influencing the Americas, Europe, Middle East & Africa, and Asia-Pacific Neurology Device Markets
Regional dynamics in the neurology devices arena reflect distinct growth catalysts and market characteristics. In the Americas, robust research and development ecosystems, comprehensive reimbursement frameworks, and early adoption cultures have established a fertile ground for high-value device penetration. The presence of leading academic institutions and clinical trial networks accelerates innovation cycles and informs evidence-based rollout strategies.
In the Europe, Middle East & Africa region, heterogeneous regulatory regimes and diverse healthcare infrastructure create both challenges and opportunities. Western Europe’s stringent approval standards drive product differentiation and clinical validation, while emerging markets in the Middle East and Africa are witnessing increased investment in neurological care capabilities. Collaborative initiatives among regional health authorities are facilitating access to advanced therapies, even as cost containment remains a primary focus.
The Asia-Pacific market is characterized by rapid expansion of healthcare infrastructure, government-led neurohealth programs, and growing middle-class demand for advanced treatments. Local manufacturing incentives and public-private partnerships are enhancing device affordability, while rising incidence of neurological disorders and greater awareness of outcomes are fueling adoption. Understanding these regional nuances is crucial for stakeholders seeking to align product strategies with localized priorities and growth trajectories
Profiling Leading Stakeholders and Competitive Strategies Driving Innovation, Partnerships, and Market Positioning in the Neurology Devices Sector
The competitive landscape of neurology devices is defined by a combination of global leaders and emerging innovators. Established medical technology companies are leveraging extensive distribution networks, deep clinical trial experience, and broad regulatory expertise to maintain market position. These organizations routinely invest in R&D to enhance product portfolios, strengthen intellectual property assets, and integrate digital capabilities such as remote monitoring and data analytics.
At the same time, mid-size enterprises and specialized firms are driving innovation in niche areas like targeted neurostimulation, bioresorbable materials, and AI-driven diagnostics. Strategic collaborations with academic centers and technology startups enable rapid iteration of proof-of-concept devices and support accelerated commercialization pathways. Mergers, acquisitions, and joint ventures continue to be prominent tactics for expanding geographic reach, securing new clinical indications, and consolidating complementary product lines.
In response to evolving patient needs and regulatory expectations, leading stakeholders are emphasizing post-market studies and real-world evidence generation. Partnerships with payers and health systems are increasingly structured to demonstrate health economics and outcomes benefits, thereby facilitating market access and reimbursement. This multifaceted competitive dynamic underscores the importance of adaptive strategies centered on innovation, collaboration, and evidence-based value propositions
Identifying Actionable Strategies for Industry Leaders to Navigate Regulatory Shifts, Technological Advances, and Evolving Clinical Needs in Neurology Devices
Industry leaders must adopt a multifaceted approach to navigate the complex neurology devices ecosystem. Companies should prioritize investments in digital health platforms that enhance remote patient monitoring and streamline data collection, enabling more responsive therapy adjustments and stronger clinical evidence. In parallel, diversifying manufacturing footprints and nurturing relationships with regional suppliers will mitigate tariff-related risks and improve supply chain resilience.
Embracing patient-centric design through co-development with clinicians and end users drives both therapeutic efficacy and market acceptance. Collaborative alliances with academic institutions, technology startups, and contract research organizations can expedite innovation cycles and support adaptive trial designs. Furthermore, leveraging real-world evidence to articulate clear health economic value will be instrumental for securing favorable reimbursement and forging partnerships with payers.
To stay ahead of regulatory shifts, organizations should maintain proactive engagement with health authorities and invest in robust post-market surveillance systems. This vigilance not only ensures compliance but also uncovers safety signals that refine product lifecycle strategies. By aligning these initiatives with targeted segmentation insights and regional priorities, companies can capitalize on emerging opportunities and solidify their leadership in the neurology devices arena
Detailing Rigorous Research Methodology Encompassing Primary Interviews, Secondary Data Review, and Qualitative-Quantitative Analyses to Ensure Data Integrity and Reliability
This study is grounded in a rigorous methodology that merges qualitative and quantitative research techniques to ensure comprehensive coverage and data integrity. Primary research efforts included in-depth interviews with key opinion leaders, clinicians, supply chain executives, and regulatory specialists, whose insights illuminated emerging trends, adoption barriers, and market dynamics across global regions.
Secondary research encompassed an extensive review of peer-reviewed journals, regulatory filings, industry publications, and published conference proceedings. This data was meticulously triangulated with proprietary databases and public financial disclosures to construct a robust framework for analysis. Quantitative modeling techniques were applied to synthesize categorical data, while sensitivity analyses tested the resilience of key findings against potential market shifts.
To maintain methodological transparency, all data sources were documented and cross-verified through internal peer review. Validation workshops with domain experts ensured that assumptions and interpretations aligned with real-world experiences. This structured approach yields a reliable foundation for stakeholders to make informed strategic decisions and confidently navigate the evolving neurology devices environment
Concluding Key Takeaways Emphasizing Strategic Implications, Market Evolution, and the Path Forward for Neurology Device Stakeholders
The neurology devices sector is undergoing transformative shifts driven by technological innovation, regulatory evolution, and changing patient care paradigms. Navigating the complexities introduced by new tariff regimes requires agile supply chain strategies and strategic partnerships. Meanwhile, in-depth segmentation insights illuminate high-potential areas such as neurostimulation, targeted stroke interventions, and home-based monitoring solutions.
Regional nuances-from the advanced reimbursement frameworks in the Americas to the infrastructure growth in Asia-Pacific and the diverse regulatory landscapes in Europe, Middle East & Africa-underscore the need for domestically tailored approaches. Competitive positioning hinges on a dual focus: continuous R&D investments that deliver clinical differentiation and robust evidence portfolios that satisfy both regulatory bodies and payers.
By integrating actionable recommendations-such as digital health investments, patient-centric co-development, and real-world evidence generation-stakeholders can respond effectively to evolving clinical needs and market dynamics. The convergence of these elements charts a clear path forward, enabling companies to secure leadership positions and drive positive patient outcomes in the neurology devices arena
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Growth and integration of AI-enabled portable EEG wearables for continuous home epilepsy monitoring
- 5.2. Advances in closed-loop deep brain stimulation devices offering adaptive therapy for Parkinson’s disease management
- 5.3. Rising adoption of noninvasive transcranial magnetic stimulation devices for treatment-resistant major depressive disorder
- 5.4. Emergence of implantable wireless neurostimulation systems with smartphone connectivity for chronic neuropathic pain relief
- 5.5. Development of high-density intracortical electrode arrays enabling real-time brain-computer interface control in paralysis rehabilitation
- 5.6. Expansion of miniaturized wearable near-infrared spectroscopy devices for noninvasive monitoring in stroke recovery programs
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Neurology Devices Market, by Product
- 8.1. CSF Management Devices
- 8.1.1. Cerebral External Drainage
- 8.1.2. Cerebral Shunts
- 8.2. Interventional Neurology
- 8.2.1. Aneurysm Coiling and Embolization
- 8.2.1.1. Embolic Coils
- 8.2.1.2. Flow Diversion Devices
- 8.2.1.3. Liquid Embolic Reagents
- 8.2.2. Cerebral Balloon Angioplasty & Stents
- 8.2.2.1. Balloon Occlusion Devices
- 8.2.2.2. Carotid Artery Stents
- 8.2.2.3. Filter Devices
- 8.2.3. Neurothromobectomy
- 8.2.3.1. Clot Retrievers
- 8.2.3.2. Snare Devices
- 8.2.3.3. Suction Aspiration Devices
- 8.2.4. Neurovascular Catheters
- 8.3. Neurostimulation
- 8.3.1. Deep Brain Stimulation
- 8.3.2. Gastric Electric Stimulation
- 8.3.3. Sacral Nerve Stimulation
- 8.3.4. Spinal Cord Stimulation
- 8.3.5. Vagus Nerve Stimulation
- 8.4. Neurosurgery Devices
- 8.4.1. Aneurysm Clips
- 8.4.2. Neuroendoscopes
- 8.4.3. Stereotactic Systems
- 8.4.4. Ultrasonic Aspirators
- 9. Neurology Devices Market, by Application
- 9.1. Chronic Pain
- 9.2. Epilepsy & Seizure Disorders
- 9.2.1. Diagnosis & Monitoring of Epilepsy
- 9.2.2. Seizure Control Devices
- 9.3. Mental Health Disorders
- 9.3.1. Anxiety
- 9.3.2. Depression
- 9.3.3. Schizophrenia
- 9.4. Multiple Sclerosis (MS)
- 9.5. Neurodegenerative Disorders
- 9.5.1. Alzheimer’s Disease
- 9.5.2. Amyotrophic Lateral Sclerosis (ALS)
- 9.5.3. Huntington’s Disease
- 9.5.4. Parkinson’s Disease
- 9.6. Neurovascular Disorders
- 9.7. Spinal Cord Injuries
- 9.8. Stroke
- 9.8.1. Hemorrhagic Stroke Devices
- 9.8.2. Ischemic Stroke Devices
- 9.8.3. Stroke Rehabilitation Devices
- 9.9. Traumatic Brain Injury (TBI)
- 10. Neurology Devices Market, by End User
- 10.1. Academic & Research Institutes
- 10.2. Diagnostic Centers
- 10.3. Home Care
- 10.4. Hospitals
- 10.5. Neurology Clinics
- 10.6. Rehabilitation Centers
- 11. Neurology Devices Market, by Distribution Channel
- 11.1. Offline
- 11.2. Online
- 12. Neurology Devices Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Neurology Devices Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Neurology Devices Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Abbott Laboratories
- 15.3.2. Acandis GmbH
- 15.3.3. B. Braun SE
- 15.3.4. Boston Scientific Corporation
- 15.3.5. Esaote SpA
- 15.3.6. GE HealthCare Technologies, Inc.
- 15.3.7. Integra LifeSciences Holdings
- 15.3.8. Koninklijke Philips N.V.
- 15.3.9. Masimo Corporation
- 15.3.10. Medtronic PLC
- 15.3.11. MicroPort Scientific Corporation
- 15.3.12. Natus Medical Inc.
- 15.3.13. Nihon Kohden Corporation
- 15.3.14. Penumbra Inc.
- 15.3.15. Rapid Medical Ltd.
- 15.3.16. Siemens Healthcare GmbH
- 15.3.17. Stryker Corporation
- 15.3.18. Terumo Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
